Your cart is currently empty!
Semaglutide Research Dosages
Below are suggested future clinical trial dosages that might be explored for weight loss research based-on studies performed for similar FDA approved GLP-1/GIP products that have already undergone several phases of clinical trials and testing.
*Administered subcutaneously 1x weekly
| Schedule | Weekly Dose in Milligrams (mg) | Weekly Dose Converted to Micrograms (mcg) |
| Week 1 – 4 | 0.25 mg | 250 mcg |
| Week 5 – 8 | 0.5 mg | 500 mcg |
| Week 9 – 12 | 1mg | 1000 mcg |
| Week 13 – 16 | 1.7 mg | 1700 mcg |
| Week 17+ (maintenance dose) | 2.4 mg | 2400 mcg |
*NOTE: This dosage schedule is for educational, and research use only. Products purchased from omegapeps.com have not been approved by the FDA for clinical studies or trials involving humans or animals at this time.
Categories
- BPC-157
- CJC-1295 (with DAC)
- CJC-1295 No Dac
- Epithalon
- Follistatin
- General Peptide
- GHK-cu (Copper Peptide)
- GnRH (Gonadotropin-Releasing Hormone)
- HCG (Human Chorionic Gonadotropin)
- Ipamorelin
- Kisspeptin
- Melanotan II (MT2)
- MK-677 (Ibutamoren)
- MOTS-c
- NAD+
- Oxytocin
- Peptide Storage
- Peptides
- PT-141 (Bremelanotide)
- Research Dosages
- Research Supplies
- Retatrutide
- Selank
- Semaglutide
- TB500 (Thymosin Beta-4)
- Tirzepatide